Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 4
2014 2
2015 4
2016 9
2017 15
2018 18
2019 28
2020 20
2021 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 33384316

94 results
Results by year
Filters applied: . Clear all
Page 1
SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now.
Taliercio JJ, Thomas G, Nakhoul GN, Vachharajani TJ, Mehdi A. Taliercio JJ, et al. Cleve Clin J Med. 2020 Dec 31;88(1):59-63. doi: 10.3949/ccjm.88a.20190. Cleve Clin J Med. 2020. PMID: 33384316 Free article. No abstract available.
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.
Dekkers CCJ, Gansevoort RT, Heerspink HJL. Dekkers CCJ, et al. Curr Diab Rep. 2018 Mar 27;18(5):27. doi: 10.1007/s11892-018-0992-6. Curr Diab Rep. 2018. PMID: 29589183 Free PMC article. Review.
Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.
Stavropoulos K, Imprialos KP, Stavropoulos N, Bouloukou S, Kerpiniotis G, Dimitriadis K, Tsioufis C, Doumas M. Stavropoulos K, et al. Cardiovasc Hematol Disord Drug Targets. 2018;18(2):120-126. doi: 10.2174/1871529X18666180206155349. Cardiovasc Hematol Disord Drug Targets. 2018. PMID: 29412122 Review.
SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
Georgianos PI, Divani M, Eleftheriadis T, Mertens PR, Liakopoulos V. Georgianos PI, et al. Curr Med Chem. 2019;26(29):5564-5578. doi: 10.2174/0929867325666180524114033. Curr Med Chem. 2019. PMID: 29792136
SGLT-2 inhibition in patients with kidney disease.
Gilbert RE. Gilbert RE. Diabetes Metab. 2014 Dec;40(6 Suppl 1):S23-7. doi: 10.1016/S1262-3636(14)72692-8. Diabetes Metab. 2014. PMID: 25554068 Review.
Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
Rajasekeran H, Cherney DZ, Lovshin JA. Rajasekeran H, et al. Curr Opin Nephrol Hypertens. 2017 Sep;26(5):358-367. doi: 10.1097/MNH.0000000000000343. Curr Opin Nephrol Hypertens. 2017. PMID: 28582367 Review.
Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
Scholtes RA, van Baar MJB, Lytvyn Y, Bjornstad P, Nieuwdorp M, Cherney DZI, van Raalte DH. Scholtes RA, et al. Diabetes Obes Metab. 2019 Apr;21 Suppl 2(Suppl 2):24-33. doi: 10.1111/dom.13692. Diabetes Obes Metab. 2019. PMID: 30843294 Free PMC article. Review.
Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats.
O'Neill J, Fasching A, Pihl L, Patinha D, Franzén S, Palm F. O'Neill J, et al. Am J Physiol Renal Physiol. 2015 Aug 1;309(3):F227-34. doi: 10.1152/ajprenal.00689.2014. Epub 2015 Jun 3. Am J Physiol Renal Physiol. 2015. PMID: 26041448 Free article.
Class effect for SGLT-2 inhibitors: a tale of 9 drugs.
Giugliano D, Esposito K. Giugliano D, et al. Cardiovasc Diabetol. 2019 Jul 23;18(1):94. doi: 10.1186/s12933-019-0899-9. Cardiovasc Diabetol. 2019. PMID: 31337395 Free PMC article.
The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers.
Hirai K, Morino J, Minato S, Kaneko S, Yanai K, Mutsuyoshi Y, Ishii H, Matsuyama M, Kitano T, Shindo M, Aomatsu A, Miyazawa H, Ito K, Ueda Y, Ookawara S, Morishita Y. Hirai K, et al. Diabetes Metab Syndr Obes. 2020 Jan 30;13:215-225. doi: 10.2147/DMSO.S229046. eCollection 2020. Diabetes Metab Syndr Obes. 2020. PMID: 32099428 Free PMC article.
94 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page